Upper Gastrointestinal BleedingTRIAGENCT03090945
Pediatric Acute Gastrointestinal Bleeding Registry
An observational study of Upper Gastrointestinal Bleeding and Gastro Intestinal Bleeding, run by Boston Children's Hospital at 3 sites in United States.
Trial summary
The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. Read more about this study
- Who is it for?
- Ages Up to 21 years
- Conditions the study is for
- Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
- What is being tested?
- This is an obsevational cohort study
- How many people
- 300 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 May 2017to 1 Dec 2023
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: All pediatric patients who present to the hospital or are currently hospitalized and presented with clinical signs of upper gastric intestinal bleeding that are severe enough that warrant the physician to perform an upper endoscopy.
Who may be able to join
- All pediatric patients will selected based on signs and symptoms of upper gastrointestinal bleeding and their need to have an upper endoscopy performed.
Who cannot join
- None
Trial locations and contacts
3 sites in 1 country.
United States3 sites, 3 recruiting
- Recruiting
Boston Childrens Hospital
Boston, Massachusetts, 02115
Michael A Manfredi, MD
- Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Lee Bass, MD
- Recruiting
Texas Children's Hospital
Houston, Texas, 77030
Douglas Fishman, MD
About this study
Official title: Pediatric Acute Bleeding Registry: Identification of Clinical, Laboratory and Endoscopic Risk Factors Associated With Pediatric Upper Gastrointestinal Bleeding
The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.
Read the detailed description
- Specific Aims/Objectives:
The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.
- Background and Significance:
Gastrointestinal (GI) hemorrhage is a potentially life-threatening presentation that the pediatric gastroenterologist must recognize, and manage appropriately. Classification is generally divided between upper or lower GI bleeding, based on the origin of bleeding relative to hemorrhages the Ligament of Treitz. The incidence of GI bleeding in children is not well established in the pediatric population. For upper GI bleeds most large, prospective studies have assessed incidence in pediatric critical care settings. In one prospective study of 984 patients, upper GI bleeds occurred in 6.4% of admissions receiving on prophylactic therapy. Other studies have shown upper GI bleeding in as many as 25% of pediatric intensive care admissions without prophylaxis. There is no data on the incidence of pediatric GI bleeds that requires endoscopic therapy.
Pediatric studies are lacking with respect to risk stratification and decisional algorithms in managing pediatric acute upper gastrointestinal bleeding. Adult literature supports accurate stratification of risk based on clinical history, physical examination, and laboratory measures. Additionally, endoscopic interventions not only allow for therapeutic interventions but also prognosticate based on visual findings. Similar pediatric literature is not available thus giving rise to large amounts of variability both center to center as well as within centers regarding management decision making.
- Design and Methods:
- Prospective, observational analysis of inpatient and ambulatory records of pediatric patients at Boston Children's Hospital beginning upon IRB approval.
- We will identify pediatric patients </= 21 years old presenting acutely to the emergency room, ambulatory clinic or as current inpatients who require endoscopic evaluation for acute upper gastrointestinal bleed and potential treatment.
- Data collected will include clinical signs and symptoms and physical exam features, laboratory studies and endoscopic findings
- Identified patients will then be followed prospectively for outcomes data collection.
- Data collection will include:
- Clinical history of bleeding onset, acuity, amount, frequency and prior history of gastrointestinal bleed.
- Medication history
- Physical examination data including vital signs (heart rate, blood pressure, and oxygen saturation)
- Laboratory data including
- Complete blood count
- Inflammatory markers (ESR and CRP)
- Liver panel
- Complete Metabolic Panel
- Urinanalysis
- Endoscopic findings as well as data from interventions (cautery, clips, injections)
- Medical management decisions (acid suppression therapy, oral intake, frequency of laboratory measurement)
- Outcome data including re-bleeding rates (with respect to endoscopic intervention), laboratory measures, and length of stay.
- Being tested
- This is an obsevational cohort study
- Keywords
- Endoscopy, GI Bleeding, Pediatrics, Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
- Medical subject headings
- Gastrointestinal Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This is an obsevational cohort studyOther
no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Develop a predictive/risk stratification algorithm for pediatric upper gastric intestinal bleeding
Identification of prognostic clinical history, physical examination, and laboratory measure risk factors that can predict/risk stratifies significant upper gastrointestinal bleeding in children.
Measured: 3 years
Secondary outcomes (5)
Medical Management Strategies
Identify successful medical management strategies in pediatric patients diagnosed with acute upper gastrointestinal bleed
Measured: 3 years
Endoscopic Management Strategies
Identify successful endoscopic and medical interventions measured by incidence rate of re-bleeding
Measured: 3 years
Re-Bleeding Risk Factors
Identify pre-existing risk factors or clinical factors associated with re-bleeding rates following initial endoscopic or surgical intervention.
Measured: 3 years
Identify Average length of Stay for Upper Gastrointestinal Bleeding
Identify length of medical stabilization and/or observation prior to either endoscopic or surgical intervention measured in hours or days in medical supervision and subsequent outcome, incidence of re-bleeding,
Measured: 3 years
Identify the incidence of significant upper gastrointestinal bleed in all pediatric hospital admission.
Identify the incidence of significant upper gastrointestinal bleed in all pediatric hospital admission.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2017
- Study start1 May 2017
- Primary completion1 Mar 2023 (estimated)
- Study completion1 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Gastrointestinal BleedingStudies of the same condition, open and under way.
- More trials run by Boston Children's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Boston Children's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Baylor College of Medicine, Children's Medical Center Dallas, University of Massachusetts, Worcester, Children's Hospital of Philadelphia, Ann & Robert H Lurie Children's Hospital of Chicago
- Responsible party
- Principal investigator, Michael A. Manfredi, MD, Boston Children's Hospital
- Investigators
- Michael A Manfredi, MD, Principal investigator, Boston Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03090945
- Sponsor's protocol ID
- P00021336
- Acronym
- TRIAGE
- Status last verified
- Sep 2020
- First submitted
- 20 Mar 2017
- Last updated
- 16 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Acute Bleeding Registry: Identification of Clinical, Laboratory and Endoscopic Risk Factors Associated With Pediatric Upper Gastrointestinal Bleeding
- ClinicalTrials.gov ID
- NCT03090945
- Acronym / sponsor ID
- TRIAGE / P00021336
- Keywords
- Endoscopy, GI Bleeding, Pediatrics, Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Boston Children's HospitalUniversity, hospital or other
- Collaborators
- Baylor College of Medicine, Children's Medical Center Dallas, University of Massachusetts, Worcester, Children's Hospital of Philadelphia, Ann & Robert H Lurie Children's Hospital of Chicago
- Study start
- 1 May 2017 (actual)
- Primary completion
- 1 Mar 2023 (estimated)
- Study completion
- 1 Dec 2023 (estimated)
- First posted
- 27 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.
Detailed description
- Specific Aims/Objectives:
The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.
- Background and Significance:
Gastrointestinal (GI) hemorrhage is a potentially life-threatening presentation that the pediatric gastroenterologist must recognize, and manage appropriately. Classification is generally divided between upper or lower GI bleeding, based on the origin of bleeding relative to hemorrhages the Ligament of Treitz. The incidence of GI bleeding in children is not well established in the pediatric population. For upper GI bleeds most large, prospective studies have assessed incidence in pediatric critical care settings. In one prospective study of 984 patients, upper GI bleeds occurred in 6.4% of admissions receiving on prophylactic therapy. Other studies have shown upper GI bleeding in as many as 25% of pediatric intensive care admissions without prophylaxis. There is no data on the incidence of pediatric GI bleeds that requires endoscopic therapy.
Pediatric studies are lacking with respect to risk stratification and decisional algorithms in managing pediatric acute upper gastrointestinal bleeding. Adult literature supports accurate stratification of risk based on clinical history, physical examination, and laboratory measures. Additionally, endoscopic interventions not only allow for therapeutic interventions but also prognosticate based on visual findings. Similar pediatric literature is not available thus giving rise to large amounts of variability both center to center as well as within centers regarding management decision making.
- Design and Methods:
- Prospective, observational analysis of inpatient and ambulatory records of pediatric patients at Boston Children's Hospital beginning upon IRB approval.
- We will identify pediatric patients </= 21 years old presenting acutely to the emergency room, ambulatory clinic or as current inpatients who require endoscopic evaluation for acute upper gastrointestinal bleed and potential treatment.
- Data collected will include clinical signs and symptoms and physical exam features, laboratory studies and endoscopic findings
- Identified patients will then be followed prospectively for outcomes data collection.
- Data collection will include:
- Clinical history of bleeding onset, acuity, amount, frequency and prior history of gastrointestinal bleed.
- Medication history
- Physical examination data including vital signs (heart rate, blood pressure, and oxygen saturation)
- Laboratory data including
- Complete blood count
- Inflammatory markers (ESR and CRP)
- Liver panel
- Complete Metabolic Panel
- Urinanalysis
- Endoscopic findings as well as data from interventions (cautery, clips, injections)
- Medical management decisions (acid suppression therapy, oral intake, frequency of laboratory measurement)
- Outcome data including re-bleeding rates (with respect to endoscopic intervention), laboratory measures, and length of stay.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
Who may qualify
- Ages
- Up to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- All pediatric patients who present to the hospital or are currently hospitalized and presented with clinical signs of upper gastric intestinal bleeding that are severe enough that warrant the physician to perform an upper endoscopy.
Key inclusion criteria (1 listed)
- All pediatric patients will selected based on signs and symptoms of upper gastrointestinal bleeding and their need to have an upper endoscopy performed.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| This is an obsevational cohort studyno intervention | Other | – |
Primary outcome
Develop a predictive/risk stratification algorithm for pediatric upper gastric intestinal bleeding
Time frame: 3 years
Identification of prognostic clinical history, physical examination, and laboratory measure risk factors that can predict/risk stratifies significant upper gastrointestinal bleeding in children.
5 secondary outcomes
Medical Management Strategies
Time frame: 3 years
Endoscopic Management Strategies
Time frame: 3 years
Re-Bleeding Risk Factors
Time frame: 3 years
Identify Average length of Stay for Upper Gastrointestinal Bleeding
Time frame: 3 years
Identify the incidence of significant upper gastrointestinal bleed in all pediatric hospital admission.
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2020.
- Individual participant dataSharing planned: No
Related trials for Upper Gastrointestinal Bleeding
Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Upper Gastrointestinal Bleeding
Recruiting
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
Not yet recruitingPhase 3
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
Ischemic Stroke, Transient Ischemic Attack
Recruiting
Detection of Blood in the GI Lumen With HemoPill Acute
Upper GI Bleeding
Active, not recruitingObservational study
Impact of Diagnostic and Therapeutic Upper and Lower Gastrointestinal Endoscopic Management on Critically Ill Patients in Fayoum University Hospitals
GIT Bleeding
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael A Manfredi, MD principal investigator
Boston Children's Hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Upper Gastrointestinal Bleeding and Gastro Intestinal Bleeding, run by Boston Children's Hospital at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michael A Manfredi, MD (617-355-6058, michael.manfredi@childrens.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Develop a predictive/risk stratification algorithm for pediatric upper gastric intestinal bleeding (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2020.